Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Most MMer’s die with multiple myeloma not from multiple myeloma. As MMers know, this blood cancer can damage the immune system, can damage the kidneys, and especially damage your bones.
If you are newly diagnosed or have relapsed you must think how to maintain bone health for the rest of your life. The content linked and excerpted below cites both conventional bisphosphonate therapies such as Zometa and Pamidronate and evidence-based non-conventional therapies such as magnesium and weight-bearing exercise.
Please consider combining current standard-of-care bone therapy, bisphosphonates, with evidence-based, non-conventional bone health therapies such vitamin D3. The final paragraph linked below explains average costs for standard-of-care bone health therapies. When I was undergoing active therapies I focused on chemotherapy regimens- what was working, what side effects occurred, those sorts of issues. I didn’t focus on the high cost of bone therapies… big mistake.
Further, please consider using the PeopleBeatingCancer Bone Health Guide to explain the pros and cons of current bone health therapies.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
I am both a long-term MM survivor and MM Cancer Coach. Have you or a loved one been diagnosed with multiple myeloma? Are you experiencing bone pain or bone damage? Scroll down the page, post a question or comment and I will reply to you ASAP.
“Patients with symptomatic multiple myeloma should receive bone-modifying therapy irrespective of evidence of lytic destruction or spinal compression fracture, according to an updated guideline from the American Society of Clinical Oncology (ASCO).
Treatment options consist of the intravenous bisphosphonates pamidronate and zoledronic acid (Zometa) or, alternatively, the RANK ligand inhibitor denosumab (Xgeva). Denosumab might be preferred over zoledronic acid for patients with renal impairment, as the RANKL inhibitor has been associated with fewer renal adverse events...
“These recommendations are consistent with the previous recommendations, with new information on denosumab,” the guideline authors stated. “Additional modifications were made to some of the recommendations on the basis of recent data to better clarify the indications for treatment, duration of treatment, and associated complications of treatment…”
The updated guideline also includes a table with the estimated cost of bone-modifying agents. Pamidronate and zoledronic acid had per-dose costs of $30.67 and $53.64, respectively, whereas each dose of denosumab cost $1,995.48. The estimated 1-year costs were $398.71 for pamidronate, $214.56 for zoledronic acid administered every 12 weeks, $697.37 for zoledronic acid every 4 weeks, and $25,9341.24 for denosumab every 4 weeks...”